Roivant Sciences Ltd.
ROIV
$10.66
$0.242.30%
Weiss Ratings | ROIV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | D+ | |||
Rating Factors | ROIV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Weak | |||
Efficiency Index | Weak | |||
Solvency Index | Excellent | |||
Total Return Index | Fair | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | ROIV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.96 | |||
Price History | ROIV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -0.37% | |||
30-Day Total Return | -6.24% | |||
60-Day Total Return | -9.97% | |||
90-Day Total Return | -7.71% | |||
Year to Date Total Return | -11.76% | |||
1-Year Total Return | 4.20% | |||
2-Year Total Return | 33.92% | |||
3-Year Total Return | 114.06% | |||
5-Year Total Return | -- | |||
52-Week High % Change | -20.18% | |||
52-Week Low % Change | 6.76% | |||
Price | ROIV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $13.06 | |||
52-Week Low Price | $9.76 | |||
52-Week Low Price (Date) | Mar 19, 2024 | |||
52-Week High Price (Date) | Sep 09, 2024 | |||
Valuation | ROIV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 7.44B | |||
Enterprise Value | 2.74B | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.15 | |||
Earnings Per Share Growth | -102.92% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 149.50 | |||
Price/Book (Q) | 1.44 | |||
Enterprise Value/Revenue (TTM) | 54.26 | |||
Price | $10.66 | |||
Enterprise Value/EBITDA (TTM) | -2.81 | |||
Enterprise Value/EBIT | -2.77 | |||
Market Cap Category | Mid Cap | |||
Dividends and Shares | ROIV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 722.72M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | ROIV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 44 20 7400 3347 | |||
Address | -- | |||
Website | roivant.com | |||
Country | United Kingdom | |||
Year Founded | 2014 | |||
Profitability | ROIV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -1,958.85% | |||
Profit Margin | -231.33% | |||
Management Effectiveness | ROIV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -9.42% | |||
Return on Equity | -- | |||
Income Statement | ROIV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 50.41M | |||
Total Revenue (TTM) | 50.41M | |||
Revenue Per Share | $0.07 | |||
Gross Profit (TTM) | -475.38M | |||
EBITDA (TTM) | -973.48M | |||
EBIT (TTM) | -987.52M | |||
Net Income (TTM) | -116.62M | |||
Net Income Avl. to Common (TTM) | -116.62M | |||
Total Revenue Growth (Q YOY) | -42.05% | |||
Earnings Growth (Q YOY) | -104.07% | |||
EPS Diluted (TTM) | -0.15 | |||
EPS Diluted Growth (Q YOY) | -96.14% | |||
Balance Sheet | ROIV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 5.15B | |||
Cash Per Share (Q) | $7.12 | |||
Total Current Assets (Q) | 5.36B | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 5.54B | |||
Current Ratio (Q) | 37.912 | |||
Book Value Per Share (Q) | $7.21 | |||
Total Assets (Q) | 5.79B | |||
Total Current Liabilities (Q) | 141.48M | |||
Total Debt (Q) | 100.31M | |||
Total Liabilities (Q) | 256.38M | |||
Total Common Equity (Q) | 5.19B | |||
Cash Flow | ROIV - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | 460.04M | |||
Cash from Financing (TTM) | -966.19M | |||
Net Change in Cash (TTM) | -1.02B | |||
Levered Free Cash Flow (TTM) | -681.00M | |||
Cash from Operations (TTM) | -508.54M | |||